Neuro Immunoassay Market Report 2026

Neuro Immunoassay Market Overview

• Neuro Immunoassay market size has reached to $2.88 billion in 2025 • Expected to grow to $4.28 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Growing Burden Of Neurological Conditions Driving Market Demand Due To Rising Prevalence And Early Diagnosis Needs • Market Trend: Developing Blood-Based Neurological Biomarker Assays To Enhance Neuro Immunoassay Diagnostics And Disease Monitoring • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neuro Immunoassay Market?

Neuro immunoassay refers to the use of immunoassay techniques specifically designed to detect and quantify biomarkers and analytes related to neurological disorders and brain function. Its primary purpose is to enable accurate diagnosis, monitoring, and research of neurological conditions through sensitive and specific biochemical assays. It also supports drug development, personalized medicine, and the understanding of neurodegenerative and neuroinflammatory diseases. The main product types of neuro immunoassay are reagents and kits, and analyzers. Reagents and kits refer to standardized assay components used to detect and quantify neurological biomarkers in biological samples, enabling the diagnosis, monitoring, and research of neurological disorders. The technologies such as radioimmunoassays, polymerase chain reaction, enzyme-linked immunosorbent assay, western blot, rapid tests, and enzyme-linked immunospot assay. The analyte or biomarker type amyloid-beta, tau protein, alpha-synuclein, neurofilament light chain, autoantibodies, cytokines, glial fibrillary acidic protein, neuron-specific enolase, ubiquitin C-terminal hydrolase L1, and brain-derived neurotrophic factor. The applications such as alzheimer’s disease, parkinson’s disease, huntington’s disease, amyotrophic lateral sclerosis, and spinal muscular atrophy, and the key end users including hospitals, clinics, academic organizations, biopharmaceutical companies, pharmaceutical companies, and others.

What Is The Neuro Immunoassay Market Growth Forecast?

The neuro immunoassay (NIA) market size is expected to see strong growth in the next few years. It will grow to $4.28 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing integration of neuro immunoassay (NIA) with artificial intelligence (AI) data analysis, rising investment in biomarker discovery, growing adoption of personalized medicine and therapeutic monitoring, expansion of high-throughput screening platforms, and a rise in demand for automated and precise immunoassay systems. Major trends in the forecast period include technology-driven innovations in assay sensitivity and specificity, advancements in artificial intelligence (AI)-enabled data interpretation, developments in multiplexed and lab-on-a-chip immunoassay systems, rising research and development in neuro biomarker identification, and innovation in integrated and automated neurodiagnostic platforms.

Global Neuro Immunoassay Market Segmentation

1) By Product Type: Reagents And Kits, Analyzers 2) By Technology: Radioimmunoassays (RIA), Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Rapid Tests, Enzyme-Linked Immunospot Assay (ELISPOT) 3) By Analyte Or Biomarker Type: Amyloid-Beta (Aβ), Tau Protein (p-Tau), Alpha-Synuclein (α-syn), Neurofilament Light Chain (NfL), Autoantibodies, Cytokines, Glial Fibrillary Acidic Protein (GFAP), Neuron-Specific Enolase (NSE), Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), Brain-Derived Neurotrophic Factor (BDNF) 4) By Application: Alzheimer’s Disease, Parkinson’s Disease (PD), Huntington’s Disease, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) 5) By End-User: Hospitals, Clinics, Academic Organizations, Biopharmaceutical Companies, Pharmaceutical Companies, Other End-Users Subsegments: 1) By Reagents And Kits: Enzyme Linked Immunosorbent Assay Reagents, Western Blotting Kits, Multiplex Assay Kits 2) By Analyzers: Automated Immunoassay Analysers, Point Of Care Immunoassay Analysers, High Throughput Immunoassay Analysers

What Is The Driver Of The Neuro Immunoassay Market?

The increasing prevalence of neurological disorders is expected to propel the growth of the neuro immunoassay market going forward. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, disrupting normal nervous system function and leading to impairments in movement, cognition, sensation, behavior, or overall bodily control. The increasing prevalence of neurological disorders is due to unhealthy lifestyle habits, including poor diet, physical inactivity, smoking, excessive alcohol consumption, and chronic stress. Neuro immunoassays help detect specific biomarkers in the nervous system, supporting early diagnosis and targeted treatment for neurological patients. For instance, in April 2024, according to the National Institutes of Health (NIH), a US-based government agency, an estimated 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and this figure is projected to nearly double to 13.8 million by 2060. Therefore, the increasing prevalence of neurological disorders drives the neuro immunoassay industry.

Key Players In The Global Neuro Immunoassay Market

Major companies operating in the neuro immunoassay market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Abcam plc, BioLegend Inc., Meso Scale Diagnostics LLC, Sino Biological Inc., Quanterix Corporation, Cusabio Technology LLC, OriGene Technologies Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., Assay Genie Ltd., Novus Biologicals LLC, Creative Diagnostics, MyBioSource Inc., Immuno-Biological Laboratories Co. Ltd., Boster Biological Technology, Cloud-Clone Corp., FineTest Biotech Inc., Abbexa Ltd.

Global Neuro Immunoassay Market Trends and Insights

Major companies operating in the neuro immunoassay market are focusing on developing advanced solutions, such as blood‑based neurological biomarker assays, to enhance disease monitoring, improve prognostic accuracy, and support clinical decision-making in neurological disorders. Blood-based neurological biomarker assays refer to tests that measure specific proteins, such as Neurofilament Light Chain (NfL), in human serum or plasma to assess neuronal injury and disease activity. For instance, in June 2024, Siemens Healthineers, a Germany-based in vitro diagnostics company, achieved CE marking for its Neurofilament Light Chain blood test designed for use on the Atellica IM Analyzer and ADVIA Centaur systems. The test quantifies NfL levels to aid prediction of neuronal injury risk in adults with relapsing multiple sclerosis, complementing clinical, imaging, and laboratory assessments, and the CE mark reflects compliance with European In Vitro Diagnostic Regulations, expanding access to standardized neuro immunoassay diagnostics across European laboratories.

What Are Latest Mergers And Acquisitions In The Neuro Immunoassay Market?

In May 2025, Sanofi, a France-based biopharmaceutical company specializing in immunology, vaccines, and neuroscience research, acquired Vigil Neuroscience Inc. for approximately $470 million. Through this acquisition, Sanofi aims to reinforce its early-stage neurology and neuroimmunology research capabilities by integrating Vigil’s oral TREM2 agonist VG 3927, a candidate targeting microglial immune pathways relevant in Alzheimer’s disease, into its development pipeline. Vigil Neuroscience Inc. is a US-based clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease, with programs centered on immune-modulating mechanisms in the central nervous system.

Regional Insights

North America was the largest region in the neuro immunoassay (NIA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuro Immunoassay Market?

The neuro immunoassay market consists of revenues earned by entities by providing services such as enzyme-linked immunosorbent assay (ELISA) kits, multiplex immunoassay platforms, chemiluminescent immunoassays, electrochemiluminescent immunoassays, and high-throughput assay systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuro immunoassay (NIA) includes sales of assay reagents, detection instruments, sample preparation kits, and automated immunoassay analyzers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neuro Immunoassay Market Report 2026?

The neuro immunoassay market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neuro immunoassay industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.